AUS
NZ
UK
CA
USA
IND
Healthcare
Ansell Limited (ASX:ANN) Set for Growth in ASX 200 Market
September 26, 2025 11:34 AM AEST| By SamDetailed analysis of Ansell Limited (ASX:ANN) highlights earnings growth, market positioning, and its role in the ASX 200, offering insights into investor confidence and future performance.
Why Sigma Healthcare’s (ASX:SIG) Growth Outlook Keeps It in Focus
September 25, 2025 04:10 PM AEST| By SamSigma Healthcare (ASX:SIG) remains in focus as its elevated valuation highlights growth expectations, market resilience, and its critical role in Australia’s pharmaceutical distribution sector.
Cann Group’s ASX Quotation Sparks Market Attention
September 25, 2025 02:12 PM AEST| By SamCann Group (ASX:CAN) strengthens its capital base by quoting new securities on ASX, reinforcing its role in the medicinal cannabis sector and highlighting growth within Australia’s evolving healthcare market.
Ryman Healthcare Joins ASX 200 Landscape
September 25, 2025 02:06 PM AEST| By SamRyman Healthcare (ASX:RYM) secures ASX listing, strengthening investor access, expanding retirement living sector visibility, and enhancing growth prospects across New Zealand and Australia through its dual market presence.
Recce Pharmaceuticals (ASX:RCE) Starts Phase 3 Diabetes Trial
September 25, 2025 01:20 PM AEST| By SamRecce Pharmaceuticals (ASX:RCE) launches Phase 3 trial for its R327G gel targeting diabetic foot infections, addressing global diabetes challenges and advancing innovative solutions within the ASX 200 biotech sector.
Lumos Diagnostics Lights Up Investor Focus at ASX SMIDcaps
September 24, 2025 03:24 PM AEST| By SamLumos Diagnostics (ASX:LDX) strengthens visibility with its ASX SMIDcaps 2025 Conference appearance, showcasing rapid point-of-care diagnostic innovations and reinforcing its position within the evolving ASX stock market healthcare landscape.
Race Oncology Advances RC220 Trial with Korean Approval
September 24, 2025 12:34 PM AEST| By SamRace Oncology (ASX:RAC) gains Korean approval for its RC220 Phase 1 trial, expanding its global clinical footprint and advancing oncology research with a novel chemotherapy combination.
Pro Medicus (ASX:PME): Is the ASX 200 Giant Undervalued?
September 24, 2025 10:41 AM AEST| By SamExplore how Pro Medicus (ASX:PME) drives healthcare innovation, combines stability with growth, and strengthens its position within the ASX 200 through advanced digital imaging solutions.
Is the Share Price Attractive in 2025 of this ASX Stock?
September 23, 2025 05:31 PM AEST| By SamSonic Healthcare (ASX:SHL) remains a global healthcare leader. This article explores its valuation, financial health, and position within the ASX 200 in 2025.
Paragon Care (ASX:PGC) and the Fundamentals Driving Market Sentiment
September 23, 2025 05:12 PM AEST| By SamParagon Care (ASX:PGC) highlights long-term growth through reinvestment and stable fundamentals, showing resilience in healthcare despite market fluctuations and reflecting broader trends in the dynamic ASX stock market.
Neurizon’s ASX Securities Move Sparks Investor Curiosity
September 23, 2025 02:18 PM AEST| By SamNeurizon Therapeutics (ASX:NUZ) advances with new securities quotation on ASX, boosting visibility and capital access while strengthening biotech representation in the evolving Australian equities and broader ASX stock market landscape.
Bio-Gene (ASX:BGT) Launches Innovative Tick Solution
September 23, 2025 11:46 AM AEST| By SamBio-Gene (ASX:BGT) demonstrates Flavocide’s strong tick control, offering durable, safe solutions for public health and veterinary markets amid rising Lyme disease concerns.
Algorae Pharma (ASX:1AI) Expands Oncology Reach ANZ
September 23, 2025 11:32 AM AEST| By SamAlgorae Pharmaceuticals (ASX:1AI) partners with Sakar Healthcare to launch five oncology medicines in Australia and New Zealand, complementing ongoing validation trials.
Is CSL (ASX:CSL) Still Misunderstood in the ASX 200?
September 22, 2025 05:54 PM AEST| By SamCSL Limited (ASX:CSL) faces cautious sentiment despite resilient fundamentals. Strong return on equity and healthcare leadership highlight its enduring role in the ASX 200 and broader Australian market landscape.
Starpharma, Genentech Partner on DEP Cancer Therapies in ASX 200
September 22, 2025 04:25 PM AEST| By SamStarpharma (ASX:SPL) partners with Genentech to develop innovative DEP-based cancer therapies, highlighting opportunities in oncology and strengthening presence in the ASX 200 landscape.
EVE Health (ASX:EVE) Drives Innovation in Women’s Health with Dyspro Launch
September 22, 2025 11:52 AM AEST| By SamEVE Health (ASX:EVE) launches Dyspro, a cannabinoid-based gummy for menstrual pain, partnering with TeleDocs Clinic for nationwide distribution in Australia.
CSL Shares: Exploring Healthcare Strength Within the ASX 200
September 19, 2025 02:29 AM AEST| By SamCSL (ASX:CSL) showcases resilience in healthcare, offering stable revenue, ethical appeal, and global growth opportunities. Positioned within the ASX 200, it remains a cornerstone of long-term market strength.
Hearing Health Matters: How ASX 200 Innovation Shapes Lives
September 18, 2025 03:06 PM AEST| By SamGlobal news links untreated hearing loss to broader health issues. ASX-listed companies like Cochlear and Audeara are providing innovative tech solutions that are integrated into everyday devices.
Proteomics International Gains ISO 15189, Boosts ASX 200 Outlook
September 18, 2025 03:05 PM AEST| By SamProteomics International (ASX:PIQ) achieves ISO 15189 certification, strengthening its precision diagnostics portfolio and advancing PromarkerEso’s potential in transforming early cancer detection and global healthcare standards.
Unlocking the Value of ResMed CDI (ASX:RMD) Shares in 2025
September 17, 2025 05:35 PM AEST| By SamExplore an in-depth analysis of ResMed CDI (ASX:RMD) shares, their financial health, revenue trends, and role within the ASX 200 for 2025 investors.
Advertise your brand on Kalkine Media